Ventyx Biosciences Inc

Ventyx Biosciences — Investor Presentation (June 2022)

37 slides from Ventyx Biosciences's investor presentation, Jun 29, 2022

  1. Slide 1: Corporate Presentation June 29, 2022

    CORPORATE PRESENTATION June 29, 2022 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Ventyx cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are

  3. Slide 3: Introduction & Pipeline

    VTX958 | TYK2 Inhibitor | Phase 1 VTX002 | S1P1R Modulator | Phase 2 VTX2735 | Peripheral NLRP3 Inhibitor | Phase 1 Complete VTX3232 | CNS-penetrant NLRP3 Inhibitor | Pre-clinical Summary | Milestones & highlights INTRODUCTION & PIPELINE

  4. Slide 4: Our Leadership Team

    BOARD OF DIRECTORS Sheila Gujrathi, MD Executive Chair, Ventyx Raju Mohan, PhD Chief Executive Officer, Founder Martin Auster, MD Chief Financial Officer Chris Krueger, JD Chief Business Officer John Nuss, PhD Chief Scientific Officer William Sandborn, MD PRESIDENT, Chief Medical Officer MANAGEMENT

  5. Slide 5: Underpinned by Strong Drug Discovery and Development Capabilities

    Our experienced team and our internal R&D engine continue to generate candidates with potential to address diseases with high unmet need Our internally-discovered small molecule drugs allow us to own 100% commercial rights to our entire portfolio with long patent lives for all product candidates Wit

  6. Slide 6: Broad Pipeline of Candidates With Multiple Near-Term Catalysts

    TARGET PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NEXT ANTICIPATED MILESTONES TYK2 VTX958 Report topline Phase 1 data Q3 2022 Initiate Phase 2 POC trials H2 2022 S1P1R VTX002 Report topline Phase 2 data 2023 NLRP3 Peripheral VTX2735 Initiate POC trial in CAPS Q4 2022 NLRP3 CNS-penetrant VTX3232 Fil

  7. Slide 7: Pipeline Targeting Large Well-Established Markets

    Indication* PATIENTS in the U.S. Global drug revenue* (2020) Target Population Psoriasis Dermatology ~8M ~$20B 25-30% moderate-to-severe Crohn’s disease IBD ~700K ~$13B 30-40% moderate-to-severe Ulcerative colitis IBD ~1M ~$7B 30-40% moderate-to-severe Psoriatic arthritis Rheumatology ~1M ~$4B 40-60

  8. Slide 8: Orally bioavailable selective allosteric inhibitor of TYK2

    ORALLY BIOAVAILABLE selective allosteric inhibitor of TYK2

  9. Slide 9: VTX958 Program Summary

    VTX958 Program Summary *Includes approved drugs Stelara™ (JNJ), Tremfya® (JNJ), Skyrizi™(ABBV), Ilumya™ (Sun Pharma) and others in late-stage development (mirikizumab (LLY), brazikumab (AZN) **Deucravacitinib efficacy reported on 16-week primary endpoint of PASI-75 (75% reduction of psoriasis affect

  10. Slide 10: VTX958 Binds Selectively to the TYK2 JH2 Domain

    Inactive Active IL-12, IL-23, IFNα Inhibited VTX958 JH2 JH1 TYK2 Features of VTX958 JH2 Allosteric Inhibition Selectivity for TYK2 JH2 vs. JAK1 JH2 domain (>4,000 X) No binding to JAK2/3 JH2 domains No binding to TYK2 kinase JH1 and No kinase enzyme inhibition of any JAK family member FERM/SH2 Recep

  11. Slide 11: VTX958 More Selective than Deucravacitinib for TYK2 JH2 Domain

    VTX958 More Selective than Deucravacitinib for TYK2 JH2 Domain Source: Ventyx internal data Deucravacitinib VTX958 TYK2-JH2 Binding Kd 0.009 nM 0.058 nM JAK1-JH2 Binding Kd 0.43 nM 240 nM Selectivity (fold) 48 >4,000 JAK1 JAK3 IL-2, IL-4 IL-13, IL-15 JAK1 JAK2 IFNγ IL-10,IL-22 IL-6 JAK1 other JAK JA

  12. Slide 12: VTX958 Selectively Targets IL-12, IL-23 and IFNα

    VTX958 Selectively Targets IL-12, IL-23 and IFNα Source: Ventyx internal data; conducted in peripheral blood mononuclear cells (PBMC) Pleiotropic Cytokines with Protective Functions Drug IL-22 IC50 (nM) IL-10 IC50 (nM) IFNγ IC50 (nM) IL-4 IC50 (nM) IL-6 IC50 (nM) VTX958 >10,000 >10,000 >10,000 >10,0

  13. Slide 13: VTX958 Phase 1 SAD Results Support Clinical Advancement

    VTX958 Phase 1 SAD Results Support Clinical Advancement NOTE: SAD = single ascending dose; AE= adverse event; dose-related exposures are observed at all doses Well-tolerated across all cohorts; all AEs observed were mild and not dose- or time-of-dose dependent No dose-saturation observed; PK and abs

  14. Slide 14: Targeting a Best-in-Class Exposure Profile With VTX958

    Targeting a Best-in-Class Exposure Profile With VTX958 Note: Exposure curves are adapted from corporate presentations and publications, as noted Allosteric TYK2 Inhibitors – Target Coverage Plasma Concentration (nM) Time (hours) Derived Concentrations (ng/mL) Time (hours) Deucravacitinib (BMS) 6mg Q

  15. Slide 15: VTX958 Profile Expected to Drive Clinical Differentiation

    VTX958 Profile Expected to Drive Clinical Differentiation Note: Solid area represents pbo-adjusted response rate; dashed area indicates total observed response rate; primary endpoint cut-off ranges from Week 10 to Week 16 Sources: Company reports and FDA labels for approved anti-IL-17 and anti-IL-23

  16. Slide 16: Unlocking the Opportunity in Crohn's Disease

    Unlocking the Opportunity in Crohn’s Disease *Source: FDA labels for approved drugs/indications; Skyrizi represents dose submitted for FDA approval. Note: maintenance dose unless otherwise specified. **Represents Phase 2 doses; specific Phase 3 doses not disclosed. Several-fold Higher Doses Required

  17. Slide 17: VTX958 Clinical Development Plan

    VTX958 Clinical Development Plan NOTE: SAD = single ascending dose; MAD = multiple ascending dose; PoC = proof-of-concept Phase 1 SAD All 7 cohorts completed Safety and exposure data allow exploration of high exposure multiples in MAD trial Phase 1 MAD Explore safety and exposure data on repeat dosi

  18. Slide 18: Peripherally restricted S1P1R modulator for ulcerative colitis

    PERIPHERALLY RESTRICTED S1P1R MODULATOR with potential for treatment of ulcerative colitis

  19. Slide 19: VTX002 Program Summary

    Phase 2 S1P1R Modulator for Ulcerative Colitis VTX002 Program Summary Ulcerative colitis is lead indication totaling up to $7B in worldwide revenue Selective S1P1R modulator Differentiated on key parameters Demonstrated pharmacodynamic activity in Phase 1 trial Pursuing clinical development plan in

  20. Slide 20: VTX002 Differentiates on Multiple Key Parameters

    Sustained lymphocyte reduction up to 65% across multiple doses in MAD trial VTX002 Differentiates on Multiple Key Parameters vs. Competitors Notes: SAE=significant adverse event; MAD=multiple ascending dose No SAEs, elevated LFTs, abnormal PFTs or macular edema No long-acting circulating metabolites

  21. Slide 21: VTX002 Differentiates on Multiple Key Parameters vs. Competitors

    VTX002 Differentiates on Multiple Key Parameters vs. Competitors Differentiating Parameter Ozanimod Etrasimod VTX002 Receptor Selectivity S1P 1,5 S1P 1,4,5 S1P 1,5 Lymphocyte Suppression in Healthy Volunteers 1 mg, ~60% 2 mg, 69% 40 mg, ~65% Lymphocyte Suppression in UC Patients 1 mg, 49% 2 mg, 40%

  22. Slide 22: Phase 1 MAD Results: Dose-Dependent Exposure and Lymphocyte Reduction

    Pharmacodynamics Pharmacokinetics Phase 1 MAD Results: Dose-Dependent Exposure and Lymphocyte Reduction Source: NEJM (2016), Gastroenterology (2020) *Ph2 UC ALC reduction from baseline: 1mg ozanimod (49%), 2mg etrasimod (40%) T1/2 of ~20 hours Dose-proportionate exposure after single and multiple do

  23. Slide 23: Phase 2 Induction Trial in Moderate-to-Severe Ulcerative Colitis

    Phase 2 Induction Trial in Moderate-to-Severe Ulcerative Colitis Baseline Week 13* Week 52 12-Week Treatment Period Patients with LOR Placebo VTX002, 60 mg VTX002, 30 mg VTX002, 60 mg VTX002, 30 mg Placebo Week 13 * includes 7-day titration Screening Period 39-Week LTE Treatment Period 13-Week Treat

  24. Slide 24: Addressable UC Patient Population in US

    Addressable UC Patient Population in US VTX002 TARGET POPULATION ~1M UC PATIENTS 300K+ moderate-to-severe UC patients ~100K biologic-treated patients >50K Existing agents leave room for new treatments Novel oral agents may expand penetrance of treated moderate-to-severe UC population beyond current

  25. Slide 25: Selective NLRP3 Inflammasome Inhibitors for systemic and CNS indications

    SELECTIVE NLRP3 INFLAMMASOME INHIBITORS for systemic and CNS indications

  26. Slide 26: Rationale for Targeting the NLRP3 Inflammasome

    Rationale for Targeting the NLRP3 Inflammasome NLRP3 = NOD-like receptor family, pyrin domain-containing protein 3; IL-1β = interleukin-1β NLRP3 Inflammasome Inhibitors Target IL-1β, a Key Driver of Inflammatory Disease The NLRP3 inflammasome can become overactive in the presence of persistent tissu

  27. Slide 27: NLRP3 Inhibitor Program Summary

    NLRP3 Inhibitor Program Summary Peripheral NLRP3 Inhibitor: VTX2735 CNS NLRP3 Inhibitor: VTX3232 Selective NLRP3 inhibitor Well tolerated in GLP safety and tox assessment Phase 1 completed with attractive safety/tolerability profile and evidence of pharmacodynamic activity Phase 2 trial in CAPS plan

  28. Slide 28: VTX2735 is a Selective & Orally Bioavailable NLRP3 Inhibitor

    VTX2735 is a Selective & Orally Bioavailable NLRP3 Inhibitor MCC950 is an NLRP3 inhibitor and a control compound used in in vitro and in vivo studies IL-1β IC50 (nM) On Target human monocytes 2 human whole blood 75 Off Target AIM2 >10000 NLRC4 >10000 NF-kb >10000 Non-Human Primate PK Mouse Pharmacod

  29. Slide 29: Summary of VTX2735 Phase 1 Results

    Summary of VTX2735 Phase 1 Results Excellent Safety and Pharmacodynamic Activity Concentration-Dependent Suppression of IL-1β Ex Vivo Safety All AEs considered mild No LFT abnormalities No dose-related increase in frequency of AEs observed PK Dose-proportionate increases in exposure (Cmax and AUC) T

  30. Slide 30: VTX2735 Has Broad Activity Against Multiple NLRP3 Mutations

    IC50 in Blood Monocyte Assay (nM) VTX2735 Has Broad Activity Against Multiple NLRP3 Mutations *Source: UCSD (Dr. Hal Hoffman’s lab); CAPS=Cryopyrin-Associated Periodic Syndromes VTX2735 blood assay data from CAPS patients suggest inhibitory activity across several mutations: FCAS, MWS and NOMID subs

  31. Slide 31: CNS-Penetrant NLRP3 Inhibitor VTX3232

    CNS-Penetrant NLRP3 Inhibitor VTX3232 In Vitro Potency & Selectivity IL-1β IC50 (nM) NLRP3 huWB 13 AIM2 BMDM >10000 NLRC4 BMDM >10000 NF-kb BMDM >10000 Rat PK (PO, 5mg/kg) T½ = 4.4 h; Oral Bioavailability = 75% Dog PK (PO, 5mg/kg) T½ = 8 h; Oral Bioavailability = 100% WB IC50 CSF Conc. ~20 x WB IC50

  32. Slide 32: NLRP3 Program Clinical Development Plan

    NLRP3 Program Clinical Development Plan COMPLETE IND-enabling Studies September 2021 IND approved Q4 2021 Initiate Phase 2 CAPS Further indications TBD Q4 2022 VTX2735 PERIPHERALLY-RESTRICTED VTX3232 CNS-PENETRANT INHIBITOR IND-Enabling Studies Potential indications include Parkinson’s, Alzheimer’s,

  33. Slide 33: Our Comprehensive NLRP3 Portfolio Targets a Broad Range of Major Inflammatory Diseases

    Our Comprehensive NLRP3 Portfolio Targets a Broad Range of Major Inflammatory Diseases NLRP3 Alzheimer’s Disease Parkinson’s Disease ALS Multiple Sclerosis Neuroinflammatory Diseases CNS-directed NLRP3 inhibitors are designed to treat a range of neuro-degenerative disorders, such as Alzheimer’s and

  34. Slide 34: Projected Pipeline Catalysts and Summary

    Projected Pipeline Catalysts and Summary

  35. Slide 35: Projected Catalysts Over Next Months

    Projected Catalysts Over Next 24 Months *Following completion of our Phase 1 trial, we intend to initiate Phase 2 trials in psoriasis, psoriatic arthritis, Crohn’s disease and potentially other indications ** Following regulatory acceptance of planned Q4 2022 IND filing, we intend to initiate and co

  36. Slide 36: Investment Highlights

    Investment Highlights Efficient & Productive Immunology Platform Internal R&D engine designed to generate candidates to address autoimmune and inflammatory diseases with high unmet need 100% commercial rights to entire portfolio; long patent life for all product candidates Potentially Differentiated

  37. Slide 37: Contact us for additional information

    Contact us for additional information: [email protected] VENTYX BIOSCIENCES, INC. 662 ENCINITAS BOULEVARD, SUITE 250 ENCINITAS, CA 92024

Ventyx Biosciences — Investor Presentation (June 2022) on 6ix